hiranandanihospital.org
Sep 17, 2024, 16:11
Amol Akhade: ESMO Presidential Today – Keynote 522 Shows Overall Survival
Amol Akhade shared a post on LinkedIn:
”ESMO presidential today.
Keynote 522 shows overall survival (OS) – positive trial.
Questions remains:
- Can we avoid adjuvant Pembrolizumab in those who get PCR post NACT ?
- Can we have biomarkers to predict this ?
- Can we have less duration of adjuvant Pembrolizumab ?
- Do we need to do something more for those who don’t get PCR ?
Slides for those who missed it Live.”
Source: Amol Akhade/LinkedIn
Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06
Dec 21, 2024, 10:38